Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 22,316 | 8,302 | 6,308 | N/A |
| Marketable Securities | 33,205 | 27,626 | 20,906 | N/A |
| TOTAL | $60,125 | $37,818 | $28,272 | $N/A |
| Non-Current Assets | ||||
| PPE Net | 2,283 | 2,547 | 3,117 | N/A |
| Other Non-Current Assets | 98 | 0 | 304 | 0 |
| TOTAL | $2,381 | $2,547 | $3,421 | $N/A |
| Total Assets | $62,506 | $40,365 | $31,693 | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Short Term Debt | 890 | 1,486 | 3,242 | N/A |
| Accounts payable and accrued liabilities | 2,073 | 2,153 | 1,533 | 0 |
| Accrued Expenses | 15,292 | 3,681 | 2,131 | N/A |
| TOTAL | $21,701 | $8,641 | $8,226 | $N/A |
| Non-Current Liabilities | ||||
| Long Term Debt | 892 | 1,044 | 1,624 | N/A |
| Deferred Revenues | 3,446 | 1,320 | 1,320 | N/A |
| Other Non-Current Liabilities | 542 | 0 | 74,514 | 0 |
| TOTAL | $1,434 | $1,044 | $76,138 | $N/A |
| Total Liabilities | $23,135 | $9,685 | $84,364 | $N/A |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 24,350 | 18,051 | N/A | N/A |
| Common Shares | 2 | 2 | 0 | N/A |
| Retained earnings | -128,418 | -94,283 | -68,366 | N/A |
| Other shareholders' equity | -639 | -1,793 | -2,499 | 0 |
| TOTAL | $39,371 | $30,680 | $-52,671 | $N/A |
| Total Liabilities And Equity | $62,506 | $40,365 | $31,693 | $0 |